OR WAIT 15 SECS
Kevin Gopal is Pharmaceutical Executive's international correspondent, covering pharma and regulatory issues around the word. He is also a political columnist for North West Business Insider, one of the UK's leading regional business magazines. He started his career as a journalist at SiYu, the UK's Chinese community magazine, before joining the PE staff.
London-Following a review of its own drug discovery capabilities, GlaxoSmithKline practically gave away its majority stake in Affymax to a group of venture capitalists led by Patricof.